Diastereomeric spirooxindoles as highly potent and efficacious MDM2 inhibitors

scientific article published on 03 May 2013

Diastereomeric spirooxindoles as highly potent and efficacious MDM2 inhibitors is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1021/JA3125417
P8608Fatcat IDrelease_vwct3hzlcjdkjhmj7tavwkp54i
P932PMC publication ID3806051
P698PubMed publication ID23641733
P5875ResearchGate publication ID236635851

P50authorJeffrey R. DeschampsQ37371382
P2093author name stringWei Sun
Denzil Bernard
Liu Liu
Shaomeng Wang
Xiaoqin Li
Yujun Zhao
Duxin Sun
Donna McEachern
Jianfeng Lu
Jean-Christophe Carry
Philippe Ochsenbein
Shanghai Yu
Vincent Ferey
P2860cites workHighly enantioselective synthesis and cellular evaluation of spirooxindoles inspired by natural productsQ39664659
Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction.Q40270647
Organocatalytic synthesis of spiro[pyrrolidin-3,3'-oxindoles] with high enantiopurity and structural diversity.Q43279699
Pteropodine and isopteropodine positively modulate the function of rat muscarinic M(1) and 5-HT(2) receptors expressed in Xenopus oocyteQ44111191
Development and optimization of a binding assay for the XIAP BIR3 domain using fluorescence polarization.Q45027288
Structure-based design of potent non-peptide MDM2 inhibitorsQ46608003
Discovery of potent antagonists of the interaction between human double minute 2 and tumor suppressor p53Q74247134
THE STRUCTURE AND STEREOISOMERISM OF THREE MITRAGYNA ALKALOIDSQ105103548
In vivo activation of the p53 pathway by small-molecule antagonists of MDM2Q27642888
Structure-based design of novel inhibitors of the MDM2-p53 interactionQ27678657
A library of spirooxindoles based on a stereoselective three-component coupling reaction.Q31134582
A Rapid Total Synthesis of Spirotryprostatin B: Proof of Its Relative and Absolute Stereochemistry F.v.N. gratefully acknowledges the Alexander-von-Humboldt-Stiftung for a Feodor-Lynen fellowship that was kindly backed by Dr. R. Breslow as second hoQ33913633
Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibitionQ36499146
Pyrrolidinyl-spirooxindole natural products as inspirations for the development of potential therapeutic agentsQ36974491
Potent and orally active small-molecule inhibitors of the MDM2-p53 interactionQ37483244
P433issue19
P407language of work or nameEnglishQ1860
P304page(s)7223-7234
P577publication date2013-05-03
P1433published inJournal of the American Chemical SocietyQ898902
P1476titleDiastereomeric spirooxindoles as highly potent and efficacious MDM2 inhibitors
P478volume135

Reverse relations

cites work (P2860)
Q37432745A potent small-molecule inhibitor of the MDM2-p53 interaction (MI-888) achieved complete and durable tumor regression in mice.
Q37620132Additive-assisted regioselective 1,3-dipolar cycloaddition of azomethine ylides with benzylideneacetone
Q26747255Catalytic asymmetric synthesis of biologically important 3-hydroxyoxindoles: an update
Q48254967Catalytic enantioselective cascade Michael/cyclization reaction of 3-isothiocyanato oxindoles with exocyclic α,β-unsaturated ketones en route to 3,2'-pyrrolidinyl bispirooxindoles
Q50228671Cerium oxide-catalyzed multicomponent condensation approach to spirooxindoles in water
Q26749008Chemical Variations on the p53 Reactivation Theme
Q45930139Counterion effects in the catalytic stereoselective synthesis of 2,3'-pyrrolidinyl spirooxindoles.
Q42099865Design of chemically stable, potent, and efficacious MDM2 inhibitors that exploit the retro-mannich ring-opening-cyclization reaction mechanism in spiro-oxindoles.
Q39608263Development of a novel immunoassay to detect interactions with the transactivation domain of p53: application to screening of new drugs
Q30670705Diaryl- and triaryl-pyrrole derivatives: inhibitors of the MDM2-p53 and MDMX-p53 protein-protein interactions†Electronic supplementary information (ESI) available: Experimental details for compound synthesis, analytical data for all compounds and in
Q33572704Discovery of 4-((3'R,4'S,5'R)-6″-Chloro-4'-(3-chloro-2-fluorophenyl)-1'-ethyl-2″-oxodispiro[cyclohexane-1,2'-pyrrolidine-3',3″-indoline]-5'-carboxamido)bicyclo[2.2.2]octane-1-carboxylic Acid (AA-115/APG-115): A Potent and Orally Active Murine [...]
Q27684218Discovery of Potent and Orally Active p53-MDM2 Inhibitors RO5353 and RO2468 for Potential Clinical Development
Q28550874Energetic Landscape of MDM2-p53 Interactions by Computational Mutagenesis of the MDM2-p53 Interaction
Q38865504Medicinal Chemistry Strategies to Disrupt the p53-MDM2/MDMX Interaction.
Q50074454Organocatalytic [3 + 2] cycloaddition of oxindole-based azomethine ylides with 3-nitrochromenes: a facile approach to enantioenriched polycyclic spirooxindole-chromane adducts
Q64106699Protoporphyrin IX is a dual inhibitor of p53/MDM2 and p53/MDM4 interactions and induces apoptosis in B-cell chronic lymphocytic leukemia cells
Q38238600Resistance acquisition to MDM2 inhibitors.
Q39205536Reviving the guardian of the genome: Small molecule activators of p53.
Q34584722SAR405838: an optimized inhibitor of MDM2-p53 interaction that induces complete and durable tumor regression
Q35411745Searching for Dual Inhibitors of the MDM2-p53 and MDMX-p53 Protein-Protein Interaction by a Scaffold-Hopping Approach
Q90328524Simple Structural Modifications Converting a Bona fide MDM2 PROTAC Degrader into a Molecular Glue Molecule: A Cautionary Tale in the Design of PROTAC Degraders
Q54992503Small Molecule Modulators of RING-Type E3 Ligases: MDM and Cullin Families as Targets.
Q35617077Small-molecule MDM2-p53 inhibitors: recent advances
Q38181445Small-molecule control of intracellular protein levels through modulation of the ubiquitin proteasome system
Q92485714Synthesis of DNA-coupled isoquinolones and pyrrolidines by solid phase ytterbium- and silver-mediated imine chemistry
Q93240867Targeted Synthesis of Complex Spiro[3H-indole-3,2'-pyrrolidin]-2(1H)-ones by Intramolecular Cyclization of Azomethine Ylides: Highly Potent MDM2-p53 Inhibitors
Q35030217Targeting MDM2-p53 interaction for cancer therapy: are we there yet?
Q47337952Targeting oncoproteins for degradation by small molecules in myeloid leukemia.
Q38749151Targeting the MDM2-p53 Protein-Protein Interaction for New Cancer Therapy: Progress and Challenges.
Q43078018Titanium(IV)-catalyzed stereoselective synthesis of spirooxindole-1-pyrrolines
Q27680560Transient Protein States in Designing Inhibitors of the MDM2-p53 Interaction

Search more.